Celltrion Inc (068270)

Currency in KRW
209,000
+3,000(+1.46%)
Closed·
Earnings results expected in 12 days
068270 is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
205,500212,000
52 wk Range
150,400251,000
Key Statistics
Bid/Ask
208,500.00 / 209,000.00
Prev. Close
206,000
Open
206,500
Day's Range
205,500-212,000
52 wk Range
150,400-251,000
Volume
448.12K
Average Volume (3m)
625.46K
1-Year Change
31.7781%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
068270 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
259,500
Upside
+24.16%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth

Celltrion Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy

Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin’s lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for rheumatoid arthritis and inflammatory bowel disease; Vegzelma for metastatic colorectal cancer and non-small cell lung cancer; Omlyclo for Asthma and urticaria; Eydenzelt for diabetic macular edema and wet age-related macular degeneration; Steqeyma for psoriasis and inflammatory bowel disease; Stoboclo/Osenvelt for osteoporosis; Avtozma for rheumatoid arthritis and active systemic juvenile idiopathic arthritis; Zymfentra for inflammatory bowel disease; and Regkirona for COVID-19, as well as CT-G07 for HIV/AIDS and Donerion Patch for Alzheimer's dementia symptoms. The company is also developing biosimilars, which are in Phase 3 clinical trials include CT-P44 for multiple myeloma, CT-P51 for melanoma and lung cancer, CT-P53 for multiple sclerosis, and CT-P55 for psoriasis, as well as CT-G20 for hypertrophic cardiomyopathy. It distributes its products in approximately 100 countries, including the United States and Europe. The company was founded in 2002 and is headquartered in Incheon, South Korea.

Compare 068270 to Peers and Sector

Metrics to compare
068270
Peers
Sector
Relationship
P/E Ratio
42.5x23.8x−0.4x
PEG Ratio
0.29−0.330.00
Price/Book
2.5x1.8x2.6x
Price / LTM Sales
10.5x2.8x3.2x
Upside (Analyst Target)
24.4%19.1%46.2%
Fair Value Upside
Unlock19.7%7.2%Unlock

Analyst Ratings

22 Buy
1 Hold
1 Sell
Ratings:
24 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 259,500
(+24.16% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Macquarie
Hold220,000.00+5.26%170,000.00Maintain22/04/2026
Nomura/Instinet
Buy270,000.00+29.19%240,000.00Maintain08/04/2026
JPMorgan
Sell200,000.00-4.31%150,000.00Maintain25/02/2026
Morgan Stanley
Hold202,000.00-3.35%198,000.00Maintain02/01/2026
Macquarie
Hold181,000.00-13.40%-Maintain31/12/2025

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4,660.00%
Dividend Yield
0.36%
Industry Median 0.46%
Annualised payout
750.00
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
05/02/2026
EPS / Forecast
2,285.89 / 1,401.69
Revenue / Forecast
1.33T / 1.25T
EPS Revisions
Last 90 days

People Also Watch

157,400
105560
-0.38%
127,100
034020
+3.67%
134,900
042660
+0.37%
788,000
009150
+1.81%
311,500
028260
-2.66%

FAQ

What Is the Celltrion (Seoul: 068270) Share Price Today?

The Celltrion stock price today is 209,000 KRW.

What Stock Exchange Does Celltrion (068270) Trade On?

Celltrion is listed and trades on the Seoul Stock Exchange.

What Is the Ticker (Stock Symbol) for Celltrion?

The stock symbol (also called a 'ticker') for Celltrion is "068270."

Does Celltrion Pay Dividends? What’s The Current 068270 Dividend Yield?

Yes, 068270 Pays Dividends to its Shareholders. The current Celltrion dividend yield is 0.36%.

What Is the Current Celltrion Market Capitalisation?

As of today, Celltrion (Seoul: 068270) market cap is 43.8T KRW.

What Is Celltrion's (068270) Earnings Per Share (TTM)?

The Celltrion EPS is currently 4,660 (Trailing Twelve Months).

When Is the Next Celltrion Earnings Date?

Celltrion's next earnings report will be released on 08/05/2026.

Is 068270 a Buy or Sell From a Technical Analyst Perspective?

Based on today's Celltrion moving averages and other technical indicators, the daily buy/sell signal for 068270 stock is Strong Buy.

How Many Times Has Celltrion Stock Split?

Celltrion has split 18 times. (See the 068270 stock split history page for full effective split date and price information.)

How Many Employees Does Celltrion Have?

Celltrion has 2680 employees, based on their latest Companies House report.

What is the current trading status of Celltrion (Seoul: 068270)?

As of 26/04/2026, Celltrion (068270) is trading at a share price of 209,000 KRW, with a previous close of 206,000 KRW. The stock has fluctuated within a day range of 205,500 KRW to 212,000 KRW, while its 52-week range spans from 150,400 KRW to 251,000 KRW.

What Is Celltrion (068270) Price Target According to Analysts?

The average 12-month price target for Celltrion is 259,500 KRW, with a high estimate of 290000 KRW and a low estimate of 200000 KRW. 22 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +24.16% Upside potential.

Industry Spotlight

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.